Nanobiotix S.A.
FRFinancials
Valuation Metrics
Nanobiotix S.A.'s Market Cap is $1.53B. At end of 2025 it was $239M. Ranked #2162 of 3,115 in US market (top 69%), #847 of 1,472 on NASDAQ (top 58%), #155 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 58%) by Market Cap.
Investment Metrics(as of 2026-10-30)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $1.53B | US#2,162/3,115 Sec#155/265 |
| Revenue | $33M | US#2,771/3,115 Sec#155/265 |
| Net Income | $-27M | US—/3,115 Sec—/265 |
| Total Assets | $80M | US#3,063/3,115 Sec#260/265 |
| Net Assets | $-99M | US#2,958/3,115 Sec#250/265 |
| Employees | 97 | US#2,626/3,115 Sec#181/265 |
| Value | ||
| P/S | 45.69x | US#2,919/3,115 Sec#166/265 |
| FCF Yield | -2.51% | US—/3,115 Sec—/265 |
| Profitability | ||
| ROA | -34.01% | US#2,910/3,115 Sec#169/265 |
| Op. Margin | -36.49% | US#2,633/3,115 Sec#107/265 |
| Financial Health | ||
| Total Debt | $112M | US#2,409/3,115 Sec#117/265 |
| FCF | $-38M | US#2,494/3,115 Sec#107/265 |
| Cash | $62M | US#2,485/3,115 Sec#213/265 |
| Current Ratio | 1.09x | US#2,145/3,115 Sec#251/265 |
| Performance | ||
| 1Y Return | 71.12% | US#114/3,115 Sec#27/265 |
| 1M Return | 1.27% | US#2,082/3,115 Sec#140/265 |
| From 52W High | -44.78% | US#2,486/3,115 Sec#178/265 |
| 1Y MDD | -61.72% | US#2,768/3,115 Sec#211/265 |
| Trading | ||
| Volume | 233,358 shares | US#2,794/3,115 Sec#256/265 |
| Trading Value | $7M | US#2,644/3,115 Sec#216/265 |
| Per Share | ||
| EPS | $-0.56 | US—/3,115 Sec—/265 |
| BPS | $-2.05 | US—/3,115 Sec—/265 |
Company Info
Nanobiotix S.A. is a clinical-stage biotechnology firm focused on developing innovative therapeutic solutions for cancer. The company's leading experimental drug, NBTXR3, is a sterile aqueous suspension comprising crystalline hafnium oxide nanoparticles. This treatment is currently undergoing development for its potential application in a broad spectrum of cancers, including soft tissue sarcoma, various head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has established a strategic collaboration with LianBio for the development and commercialization of NBTXR3 within key Asian markets, specifically Greater China, South Korea, Singapore, and Thailand. Founded in 2003, the company's main operations are situated in Paris, France.